TD Cowen Maintains Buy on Intra-Cellular Therapies, Raises Price Target to $90
Portfolio Pulse from Benzinga Newsdesk
TD Cowen analyst Joseph Thome has maintained a Buy rating on Intra-Cellular Therapies (NASDAQ:ITCI) and increased the price target from $80 to $90, indicating a positive outlook on the company's stock.
April 17, 2024 | 10:15 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
TD Cowen analyst Joseph Thome reaffirmed a Buy rating on Intra-Cellular Therapies and raised the price target to $90 from $80.
The increase in price target by a reputable analyst like Joseph Thome from TD Cowen suggests a strong confidence in Intra-Cellular Therapies' future performance. This endorsement is likely to positively influence investor sentiment and potentially drive up the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100